SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION

被引：0
|
作者：
Suda, Kenichi [1 ]
Mizuuchi, Hiroshi [1 ]
Sato, Katsuaki [1 ]
Takemoto, Toshiki [1 ]
Iwasaki, Takuya [1 ]
Minami, Kenji [1 ]
Yatabe, Yasushi [2 ]
Mitsudomi, Tetsuya [1 ]
机构：
[1] Kinki Univ, Fac Med, Dept Surg, Div Thorac Surg, Higashiosaka, Osaka 577, Japan
[2] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutation; EGFR tyrosine kinase inhibitors; acquired resistance; molecular target therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.05-010
引用
收藏
页码：S771 / S772
页数：2
相关论文
共 50 条
  • [1] Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
    Zhuang, W.
    Xu, C.
    Wang, W.
    Song, Z.
    Zhu, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Fang, M.
    Chen, G.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
    Yamaoka, Toshimitsu
    Ohmori, Tohru
    Ohba, Motoi
    Arata, Satoru
    Kishino, Yasunari
    Murata, Yasunori
    Kusumoto, Sojiro
    Ishida, Hiroo
    Shirai, Takao
    Hirose, Takashi
    Ohnishi, Tsukasa
    Sasaki, Yasutsuna
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
  • [3] EXPRESSION OF NOTCH-1 IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA
    Xie, M.
    He, C. -S.
    Hou, J. -H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [4] Epithelial-Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
    Uramoto, Hidetaka
    Iwata, Teruo
    Onitsuka, Takamitsu
    Shimokawa, Hidehiko
    Hanagiri, Takeshi
    Oyama, Tsunehiro
    ANTICANCER RESEARCH, 2010, 30 (07) : 2513 - 2517
  • [5] The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
    Chung, Fu-Tsai
    Ho, Ming-Yun
    Fang, Yueh-Fu
    Hshieh, Meng-Heng
    Wang, Tsai-Yu
    Kuo, Chih-Hsi
    Chen, Hao-Cheng
    Wang, Chun-Hwa
    Lin, Shu-Min
    Yu, Chih-Teng
    Lin, Horng-Chyuan
    Kuo, Han-Pin
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [6] RELEVANCE BETWEEN CEA LEVEL AND EGFR MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH LUNG ADENOCARCINOMA
    Zhang, Wei Y.
    Han, Hui B.
    Jin, Bo
    Shao, Hua M.
    Dong, Yu
    Huang, Mi A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S891 - S891
  • [7] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [8] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
    Izumi, Hiroto
    Kanda, Rina
    Murakami, Yuichi
    Morimoto, Yasuo
    Ono, Mayumi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [9] NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI
    Facchinetti, Francesco
    Tiseo, Marcello
    Gnetti, Letizia
    Silini, Enrico Maria
    Ardizzoni, Andrea
    LUNG CANCER, 2013, 82 (01) : 177 - 178
  • [10] Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Tsai, Meen-Hsin
    Yu, Sung-Liang
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 603 - 610
12345